Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength?

Group 1 - IDEAYA Biosciences, Inc. (IDYA) shares increased by 15.3% to close at $39.51, following a notable trading volume compared to typical sessions, contrasting with a 9.9% loss over the past four weeks [1][2] - The stock price surge was driven by positive clinical data from a phase II study of IDE397, which targets MTAP-deletion urothelial and non-small cell lung cancer (NSCLC) patients, showing promising responses and durability of treatment [2] - The phase II clinical data involved 18 evaluable patients, including seven with urothelial cancer, four with adenocarcinoma NSCLC, and seven with squamous NSCLC, indicating significant clinical proof-of-concept for IDE397 [2] Group 2 - The consensus EPS estimate for IDEAYA has remained unchanged over the last 30 days, suggesting that stock price movements may not sustain without trends in earnings estimate revisions [4] - The stock is part of the Zacks Medical - Biomedical and Genetics industry, where another company, Lexicon Pharmaceuticals (LXRX), experienced a 4.2% decline, reflecting a -4.6% return over the past month [7]